First ‘tumour agnostic’ indication announced
Australians who have a cancer which displays a specific biomarker may be eligible for treatment with a medicine that activates the immune system to fight cancer cells.
A medicine to treat cancer based on the genetic profile of the tumour, rather than tumour type or location, has now been registered on the Australian Register of Therapeutic Goods < 263932>.2 This marks the first ‘tumour agnostic’ approach to cancer treatment in Australia.1,2,4
MSD confirmed that KEYTRUDA can now be used to treat eligible patients whose cancer has a specific genetic alteration (known medically as a biomarker) called deficient DNA-mismatch repair (dMMR) or microsatellite instability-high (MSI-H). These patients must have advanced cancer (where the cancer has spread to other organs) that has progressed following prior treatment and have no satisfactory alternative treatment options.
Read more on this story at: https://www.medianet.com.au/releases/177552/